Trials
Search / Trial NCT06434272

Blood Flow Restriction Exercise in Patients with an Achilles Tendon Rupture

Launched by UNIVERSITY OF AARHUS · May 23, 2024

Apply for Trial

Trial Information

Current as of March 14, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is looking at a type of exercise called Blood Flow Restriction Exercise (BFRE) to see if it helps patients recover better from an Achilles tendon rupture. Researchers want to know if adding BFRE to standard care makes a difference and whether starting this exercise early (within the first 12 weeks) or later (between 13-24 weeks) is more beneficial. Participants will follow a 12-week BFRE program alongside their usual treatment, and the effects will be compared at 3 months and again at 6 months after the injury.

To be eligible for this study, participants need to be at least 18 years old and have begun treatment for their Achilles tendon rupture within 72 hours of the injury. They should also be able to understand Danish. However, people with certain conditions, like diabetes or a previous Achilles tendon rupture, cannot join the trial. Those who take certain medications or have specific health issues affecting their legs will also be excluded. Participants can expect to engage in a structured exercise program while receiving regular care, and their progress will be monitored throughout the study.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • aged 18 years or older
  • • have started initial treatment within 72 hours of Achilles tendon rupture
  • • understand written and spoken Danish
  • Exclusion Criteria:
  • • bilateral Achilles tendon rupture
  • • previous Achilles tendon rupture in either leg
  • • decreased lower extremity function, caused by conditions other than Achilles tendon rupture
  • • treated with fluoroquinolones or corticosteroids within the last six months
  • • diabetes
  • • previous diagnosed thrombosis
  • • Known atherosclerosis in the peripheral arteries of the lower limb
  • • other reasons for exclusion (cognitive deficits, inability to provide informed consent, requiring cast-treatment due to low compliance regarding gradual wedge removal, etc.)

Trial Officials

Andreas Bentzen, MHSc

Principal Investigator

University of Aarhus

Inger Mechlenburg, DMSc

Study Director

University of Aarhus

Per H. Gundtoft, MD, PhD

Study Director

Aarhus University Hospital

Stian L. Jørgensen, PT, PhD

Study Director

Regional Hospital Horsens

About University Of Aarhus

The University of Aarhus, a prestigious research institution located in Denmark, is dedicated to advancing medical science through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university fosters an environment that encourages cutting-edge research and the development of novel therapeutic interventions. Committed to ethical standards and patient safety, the University of Aarhus aims to contribute to the global body of medical knowledge while enhancing healthcare outcomes through rigorous scientific inquiry and evidence-based practices.

Locations

Aarhus N, , Denmark

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0